A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma
Primary Sponsor
Collaborating Groups
TROG Cancer Research
Accrual Target
412
Final Accrual
415
Closing Date of Accrual
20 August 2024
Trial Chairperson
Prof Sandro Porceddu - Princess Alexandra Hospital
Trial Contact
qa@trog.com.au
Related Post
5 March, 2025
All Australian sites open for SOCRATES HCC trial
5 March 2025: TRIAL UPDATE We’re excited to have
4 March, 2025
TRIAL IN FOCUS: DCIS delivers valuable evidence
4 March 2025: A decade on from the last
